Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Acquires Rights to KRAS G12C Candidate in $312 Million Pact

publication date: Sep 2, 2021

Suzhou Innovent acquired greater China rights to GenFleet's lead KRAS G12C oncology candidate in a $312 million agreement. GenFleet is a Shanghai clinical-stage biotech focused on novel oncology and immunology targets. Innovent will pay $22 million upfront, invest $50 million in global development support (if Innovent exercises its global option), and make up to $240 million in milestone payments. GenFleet's KRAS G12C candidate, GFH925, was recently approved to start China trials in patients with cancers that have a KRAS G12C mutation. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here